Awards Nomination 20+ Million Readerbase
Indexed In
  • Academic Journals Database
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • Scimago
  • Ulrich's Periodicals Directory
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • Publons
  • MIAR
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
Share This Page

Yuki Saito

Publications
  • Research Article
    A Human B cell Receptor Epitope-Based Erbb-2 Peptide (N: 163-182)with Pan-Reactivity to the T cells of Japanese Breast Cancer Patients
    Author(s): Banri Tsuda, Yoshie Kametani, Yumiko Goto, Yuki Saito, Yasuhiro Suzuki, Sonoko Habu, Hidetoshi Inoko and Yutaka TokudaBanri Tsuda, Yoshie Kametani, Yumiko Goto, Yuki Saito, Yasuhiro Suzuki, Sonoko Habu, Hidetoshi Inoko and Yutaka Tokuda

    Background: While monoclonal antibodies are widely accepted as being powerful in molecular targeting therapy, the activation of immunity by the B cell receptor epitope peptide has not been reported. Our objective was to evaluate a 20-mer multiple antigen peptide containing the anti-erbB-2 (HER2/neu) monoclonal antibody epitope (N: 163–182), designated as CH401MAP, as a general peptide vaccine for Japanese breast cancer patients. Methods: The 20-mer CH401 epitope peptide binding to the human leukocyte antigen (HLA) of Japanese breast cancer patients was predicted by algorithms from the following databases: SYFPEITHI, Bioinformatics and Molecular Analysis Section (BIMAS), and Immune Epitope Database (IEDB). Peripheral blood mononuclear cells (PBMCs) were collected from 173 breast cancer patients and stimulated with the peptide in vitro. Cytokine secretion was examined by enzyme-li.. View More»
    DOI: 10.4172/2157-7560.1000159

    Abstract PDF